Phase 2 N=23 Study of Plasma Exchange in Severe COVID-19
COVID19
Primary: Number of Participants With Inflammatory Marker Reduction of at Least 50% at Any Efficacy Time Point — 5; 8 Participants — p=0.16
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=20 Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity
COVID-19
Primary: Plasma Viscosity — 2.35; 2.47; 1.61; 2.47 cP
Phase 2 N=13 Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Primary: Changes From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) — -1.0; -1.5; -4.0; -5.5 units on a scale — p=<0.0001
Phase 2 N=42 Efficacy and Safety of Plasma Exchange With 5% Albumin in Beta-amyloid Peptide Clearance in Cerebral Spinal Fluid
Alzheimer's Disease
Primary: Change From Baseline in Aβ1-42 Cerebrospinal Fluid (CSF) Levels. — 75.3; -45.5; -86.2; -283.0 pg/mL
N/A N=38 Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients
COVID-19 Pneumonia · COVID-19 Respiratory Infection · Acute Respiratory Failure
Primary: Survival — 9; 5 Participants
Phase 3 N=37 Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device
Autoimmune Diseases · Renal Disorders · Hematologic Disorders
Primary: Percent Efficiency of Plasma Removal During the Therapeutic Plasma Exchange Procedure — 81.9; 75.2 percentage of plasma removal efficiency — p=<0.001
Phase 3 N=704 Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
Granulomatosis With Polyangiitis (Wegener's) (GPA) · Microscopic Polyangiitis (MPA)
Primary: Composite of i) All-cause Mortality or ii) End-stage Renal Disease — 100; 109 Participants
Phase 2 N=12 Efficacy and Safety of Plasma Exchange With Albutein® 5% in Participants With Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Primary: Change From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score — 39.8; -1.3; -2.5; -5.0 units on scale
Phase 4 N=41 Octaplas Pediatric Plasma Exchange Trial
Adverse Effects in the Therapeutic Use of Plasma Substitutes
Primary: Monitoring of Adverse Drug Reactions Caused by the Octaplas™Used for Plasma Exchange. — 0; 5; 3; 8 event
Phase 3 N=26 Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)
Thrombotic Thrombocytopenic Purpura
Primary: Number of Participants With Exacerbations in the CSA/PEX Arm Compared to the Steroids/PEX Arm — 3; 1 participants
Phase 2 N=51 Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis, Acute Fatal Form
Primary: %Survival — 44; 7 percentage of participants
Phase 2 N=20 Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS
Cytokine Release Syndrome · COVID19
Primary: C-reactive Protein (CRP) Levels at Baseline and Day 14 — 75.45; 59.8; 41.9; 38.7 mg/L
Phase 2 N=9 Combined PEX, Rituximab and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
IPF
Primary: Number of Participants With Respiratory and/or Hemodynamic Deteriorations — 1; 3 Participants
Phase 2 N=19 Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Purpura
Primary: Incidence of the Composite Primary Outcome of Exacerbation or Refractory TTP — 2; 0 Participants
N/A N=26 A Randomized Trial Examining Plasma Exchange Using the Becton Dickinson (BD) Catheter In an Outpatient Apheresis Unit
Plasma Exchange
Primary: Efficacy of Assigned Intervention as Measured by Plasma Hemoglobin Value — 16.8; 17.3 g/dL — p=0.87
N/A N=3,443 IMPACT (Improving Plasma Collection) Clinical Trial
Apheresis Related Hypotension
Primary: Rate of Significant Hypotensive Adverse Events — .035; .051 % of significant hypotensive AEs
Phase 2 N=223 Plasma Therapy of COVID-19 in Severely Ill Patients
SARS-CoV-2 Infection
Primary: Number of Participants With Day 28 Severity Outcomes Using a 7-point Ordinal Scale of Clinical Status — 108; 48; 3; 2 Participants
Early Phase 1 N=60 Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)
Chronic Graft Versus Host Disease
Primary: Number of Participants With an Overall Response at Week 28 — 20; 14 Participants — p=0.373
N/A N=73 Evaluation of Spectra Optia Red Blood Cell Exchange in Sickle Cell Patients
Sickle Cell Disease
Primary: Mean Ratio Actual Fraction of Cells Remaining (FCRa; as Measured by Post-Procedure % HbS) to the Predicted Fraction of Cells Remaining (FCRp; as Predicted by the Spectra…
Phase 2 N=23 Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
Pemphigus
Primary: Number of Patients Achieving a Short- and Long-term Remission of Pemphigus — 23 Participants
Phase 3 N=523 PreHospital Air Medical Plasma Trial
Hemmorhagic Shock During Air Medical Transport
Primary: Our Primary Outcome for the Proposal Will be 30 Day Mortality — 53; 89 Participants
Phase 2 N=81 Photopheresis for the Treatment of Acute Graft Versus Host Disease
Graft Versus Host Disease
Primary: Day 56 Treatment Success — 57; 72; 43; 47 percentage of participants
Phase 4 N=50 Octaplas Pediatric Plasma Replacement Trial
Liver Surgery · Liver Dysfunction · Coagulopathy
Primary: Number of Participants With Adverse Drug Reactions (e.g., Allergic Reactions, TEs, TEEs (Thromboembolic Events) and Hyperfibrinolytic Events) — 5; 0; 0; 0 participants
Phase 3 N=51 Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Purpura
Primary: Percentage of Participants Who Achieved Remission Without Requirement of Therapeutic Plasma Exchange During Overall Study Period — 93.5 percentage of participants
Phase 4 N=26 Panel Reactive Antibody (PRA) Reduction in Sensitized Patients Awaiting Renal Transplantation
End Stage Renal Disease
Primary: The Percent of Sensitized Patients Treated With PRA Reduction Pharmacological Therapy, Including Cytogam, Who Become Cross-match Compatible With Potential Living Donor…
N/A N=18 (H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol
Hypercholesterolemia
Primary: Percent Change in Pre- and Post-treatment Reductions of Low-density Lipoprotein Cholesterol (LDL-C) Levels Between the Approved H.E.L.P. System and the Modified H.E.L.P…
Phase 2 N=10 Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
Thrombocytopenia · Alloimmune Platelet Refractoriness
Primary: Number of Subjects With Sustained Platelet Transfusion Responsiveness — 4 Participants
Phase 4 N=50 Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease
Liver Disease
Primary: Number of Participants That Reached Targeted International Normalized Ratio (INR) Within ±0.1 After First Fresh Frozen Plasma (FFP) Transfusion Completed. — 7; 17…
Phase 2 N=29 An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients
Kidney Transplant Rejection
Primary: Maximum Reduction in Donor Specific Antibodies (DSA) Level During the 5 Days Following the Start of Treatment — 94; 36 percentage of maximum DSA reduction
Phase 1 N=16 The Stanford Parkinson's Disease Plasma Study
Parkinson Disease(PD)
Primary: Number of Related and Unrelated Adverse Events — 14; 3; 36 events